Access is limited to SLU faculty, students, or staff from on-campus or off. Enter your SLU Net ID (SLU e-mail username) and SLU Net ID password, if requested by the SLU EZproxy.

Wolters Kluwer, a Dutch publishing company specializing in medical and tax information, found itself in a similar uncertain ...

The Global Financial Development Database is an extensive dataset of financial system characteristics for 214 economies. It contains annual data, starting from 1960. It has been last updated in ...

Finch-Race, Daniel A. 2015. La retorica di Ulisse contro lapietas, da Dante a Tennyson. Romance Studies, Vol. 33, Issue. 2, p. 107. Ovid's Heroides, a collection of twenty-one epistles in elegiac ...

Ovid’s playful poetry made him a favorite among Rome’s elite, but angered Emperor Augustus. Just as he was producing his finest work, Ovid (43 BC – 17 AD) was exiled to the darkest corner of ...

The PubMed and Ovid databases were searched using the mesh term "heart rate variability" and: "short""term""short-term" and "five." A second search using 13 terms in conjunction with the previous ...

The English-language literature was reviewed, utilizing databases for Ovid MEDLINE, International Pharmaceutical Abstracts, the Excerpta Medica Database, the Cochrane Database of Systematic ...

Comprising fifteen books and over two hundred and fifty myths, Ovid's Metamorphoses is one of the longest extant Latin poems from the ancient world and one of the most influential works in Western ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Covid-19 continues to be a powerful risk factor for future heart attacks and strokes for almost three years following the ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

BTIG analyst Thomas Shrader maintained a Buy rating on Ovid Therapeutics (OVID – Research Report) yesterday and set a price target of $5.00. Thomas Shrader’s rating is based on a combination ...